CN112972696B - 荧光多肽掺杂金属有机框架纳米材料及制备方法和应用 - Google Patents
荧光多肽掺杂金属有机框架纳米材料及制备方法和应用 Download PDFInfo
- Publication number
- CN112972696B CN112972696B CN202110221727.2A CN202110221727A CN112972696B CN 112972696 B CN112972696 B CN 112972696B CN 202110221727 A CN202110221727 A CN 202110221727A CN 112972696 B CN112972696 B CN 112972696B
- Authority
- CN
- China
- Prior art keywords
- solution
- polypeptide
- zif
- preparation
- organic framework
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 47
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 44
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000012621 metal-organic framework Substances 0.000 title claims abstract description 17
- 239000002086 nanomaterial Substances 0.000 title claims abstract description 13
- 239000013154 zeolitic imidazolate framework-8 Substances 0.000 claims abstract description 45
- MFLKDEMTKSVIBK-UHFFFAOYSA-N zinc;2-methylimidazol-3-ide Chemical compound [Zn+2].CC1=NC=C[N-]1.CC1=NC=C[N-]1 MFLKDEMTKSVIBK-UHFFFAOYSA-N 0.000 claims abstract description 45
- 239000000243 solution Substances 0.000 claims abstract description 43
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 23
- 229940079593 drug Drugs 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000002245 particle Substances 0.000 claims abstract description 12
- 238000003756 stirring Methods 0.000 claims abstract description 11
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000001035 drying Methods 0.000 claims abstract description 10
- 239000006228 supernatant Substances 0.000 claims abstract description 10
- 239000012153 distilled water Substances 0.000 claims abstract description 9
- 239000011701 zinc Substances 0.000 claims abstract description 8
- 239000011259 mixed solution Substances 0.000 claims abstract description 6
- 238000005406 washing Methods 0.000 claims abstract description 5
- 238000010257 thawing Methods 0.000 claims abstract description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 28
- 239000007850 fluorescent dye Substances 0.000 claims description 10
- 229960004679 doxorubicin Drugs 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 229940041181 antineoplastic drug Drugs 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 230000035699 permeability Effects 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims 4
- 238000005119 centrifugation Methods 0.000 claims 1
- 150000002411 histidines Chemical class 0.000 claims 1
- 239000013049 sediment Substances 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
- 238000011068 loading method Methods 0.000 abstract description 11
- 238000012382 advanced drug delivery Methods 0.000 abstract description 2
- 238000010276 construction Methods 0.000 abstract description 2
- 238000001514 detection method Methods 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 239000007787 solid Substances 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 7
- 229940009456 adriamycin Drugs 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N methylimidazole Chemical group CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 7
- 239000000463 material Substances 0.000 description 5
- 238000009210 therapy by ultrasound Methods 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000002189 fluorescence spectrum Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000008204 material by function Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910052665 sodalite Inorganic materials 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 238000002284 excitation--emission spectrum Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 239000002114 nanocomposite Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011232 storage material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0089—Particulate, powder, adsorbate, bead, sphere
- A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
- A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nanotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Composite Materials (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Manufacturing & Machinery (AREA)
- Immunology (AREA)
- Optics & Photonics (AREA)
- Materials Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种荧光多肽掺杂金属有机框架纳米材料及制备方法和应用。将冷冻的5‑FAM多肽溶液室温下解冻并溶于蒸馏水中得到溶液一，将Zn(NO3)2·6H2O溶于蒸馏水中，置于磁力搅拌器上进行搅拌得到溶液二；将溶液一缓慢加入溶液二中得到混合溶液；室温搅拌0.5‑1h，将2‑甲基咪唑溶液迅速加入到所述混合溶液中；所有操作均在室温下进行；锌离子与2‑甲基咪唑的摩尔比为1:30‑1:80；静置后离心；移除上层清液，得到的颗粒用水冲洗将沉积物在40‑60℃减压干燥12‑15h，得到荧光多肽掺杂金属有机框架纳米材料5‑FP/ZIF‑8。本研究以简单高效的策略将药物装载和检测环节整合到单一平台，为生物医学领域先进药物输送系统的建设开辟了一条新途径。
Description
技术领域
本发明涉及荧光标签修饰的多肽掺杂金属有机框架的制备方法，属于纳米功能材料领域，尤其涉及的是一种荧光多肽掺杂金属有机框架纳米材料及制备方法和应用。
背景技术
ZIF-8是由锌离子与2-甲基咪唑配位组装而成的多孔结晶材料。它具有比表面积大、气孔率高、合成方便、尺寸可控等优点，在功能材料的封装和输送方面具有突出优势。ZIF-8是研究最多的一个MOF材料方钠石(SOD)拓扑结构,表现出一个三维结构形成的锌离子和甲基咪唑链接器。使其具有直径11.6°A的大孔保持架，具有较高的热稳定性，耐水化学性能显著。
目前的大多数抗肿瘤药物存在选择性低、毒副作用强、易产生耐药性等缺点，迫切需要研究和开发新的抗肿瘤药物。人们通过实验发现许多实体瘤的细胞外pH值比正常组织要低。基于这样的机理，设计具有pH响应的肿瘤药物包覆材料，使之能区分正常组织和肿瘤。
目前大多数药物存在选择性低、毒副作用强、易产生耐药等缺点，极大地限制了其临床应用。因此，为了克服这些固有的局限性，进一步满足人们对有效治疗日益增长的需求，设计一种可控的给药系统用于癌症治疗具有重要意义。因此，我们需要一种有效的载药和给药手段来减少对体内正常细胞的损伤。脂质、聚合物纳米粒子、金属团簇和碳结构在过去已经被测试为药物存储材料。然而，这些材料有几个局限性，如载药量低(<5wt％)，药物释放快，毒性大。
发明内容
本发明针对现有技术的不足提供一种荧光多肽掺杂金属有机框架纳米材料及制备方法和应用。通过在ZIF-8上添加荧光标记的组氨酸多肽，我们得到了荧光标记的多肽掺杂的ZIF-8(称为5-FP/ZIF-8)。体外研究表明，5-FP/ZIF-8具有很好的智能pH响应性，组氨酸多肽的添加增强了细胞的通透性。同时，荧光标签在药物的载入和释放时可以产生荧光反应。本研究以简单高效的策略将药物装载和检测环节整合到单一平台，为生物医学领域先进药物输送系统的建设开辟了一条新途径。
本发明的技术方案为：
一种荧光多肽掺杂金属有机框架纳米材料的制备方法，包括以下步骤：
(1)制备荧光标签修饰的多肽掺杂的ZIF-8：将冷冻的5-FAM多肽溶液室温下解冻并溶于蒸馏水中得到溶液一，另外将Zn(NO3)2·6H2O溶于蒸馏水中，置于磁力搅拌器上进行搅拌得到溶液二；将溶液一缓慢加入溶液二中得到混合溶液；室温搅拌0.5-1h，将2-甲基咪唑溶液迅速加入到所述混合溶液中；所有操作均在室温下进行；锌离子与2-甲基咪唑的摩尔比为1:30-1:80；
(2)静置24-36h,6000-8000rpm离心；移除上层清液，得到的颗粒用水冲洗将沉积物在40-60℃减压干燥12-15h，得到荧光多肽掺杂金属有机框架纳米材料5-FP/ZIF-8。
所述的制备方法，步骤(1)中：5-FAM肽与锌离子的摩尔比为1：250-500。
所述的制备方法，步骤(1)所加入的荧光标签5-FAM替换为6-FAM、FITC或cy5。
所述的制备方法，步骤(1)，加入500uL 0.25mol/L的Zn(NO3)2·6H2O溶液，5mL2mol/L的2-甲基咪唑溶液。
所述的制备方法，步骤(2)所述的将沉淀溶液离心中，为中低速离心，离心机转速为6000-8000转/分，时间为20-30min。
所述的制备方法，步骤(2)中沉淀洗涤三次，直至呈微碱性，为充分洗涤每次超声5-10min。
所述的制备方法，步骤(2)中减压干燥时温度不超过60℃，直至彻底干燥。
根据任一所述的制备方法获得的荧光多肽掺杂金属有机框架纳米材料。
所述的荧光多肽掺杂金属有机框架纳米材料在制备抗癌药物中的应用。
所述的应用，所述抗癌药物为阿霉素、柔红霉素或环磷酰胺。
本发明的有益效果是：5-FP/ZIF-8纳米复合材料可以作为一种高效的pH响应型药物传递系统，在pH为6.3时能够缓慢释放所载药物。5-FAM荧光标记可有效检测药物的装载和释放，5-FAM的荧光强烈依赖于药品载入的量，随药物载入量的增加荧光减弱。当药物释放后荧光恢复。由于组氨酸多肽的存在，细胞膜的穿透和破裂增加了其通透性，这更有利于药物特异性识别和进入癌细胞，降低活性，加速癌细胞的死亡。可为开发一种用于癌症治疗的智能pH敏感给药系统提供新的机会。
附图说明
图1为带有荧光标签修饰的多肽掺杂金属有机框架的制备方法与应用的流程图。
图2为5-FAM多肽掺杂ZIF-8的SEM图像。
图3为TEM图像。
图4为5-FAM多肽掺杂ZIF-8的荧光激发发射光谱。
图5为5-FAM多肽掺杂ZIF-8载入阿霉素的荧光淬灭光谱。
图6为5-FAM多肽掺杂ZIF-8浸泡于pH为6.3的PBS溶液的荧光恢复光谱。
图7为5-FAM多肽掺杂ZIF-8浸泡于pH为6.8的PBS溶液的荧光恢复光谱。
图8为负载阿霉素的5-FAM多肽掺杂ZIF-8浸泡于pH为6.3的PBS溶液的透射图。
图9为细胞实验的共聚焦显微镜图。
具体实施方式
以下结合具体实施例，对本发明进行详细说明。
实施例1
制备荧光标签修饰的多肽掺杂的ZIF-8：将冷冻的5-FAM多肽溶液室温下解冻，另外将其溶于蒸馏水中，置于磁力搅拌器上进行搅拌。将Zn(NO3)2·6H2O配成0.25mol/L的水溶液。另外，将2-甲基咪唑配成1mol/L的水溶液。取5uM的5-FAM多肽100uL加入到500uLZn(NO3)2·6H2O溶液中搅拌10min，将5mL甲基咪唑溶液迅速加入到上述溶液中，室温搅拌0.5h，所有操作均在室温下进行，锌离子与甲基咪唑的摩尔比为1:40。混合各组分溶液后，混合物立即变得混浊。静置24-36h,6000-8000rpm离心10min。移除上层清液。得到的颗粒用水冲洗三次；最后，将沉积物在40-60℃减压干燥12-15h。
称取2g 5-FAM标记的多肽掺杂的ZIF-8固体并加入2ml水，超声5-10min，然后加入0～100μM不同浓度的阿霉素标准溶液，5分钟后离心，离心机转速为6000转/分，移走上清液，真空干燥，温度不超过40℃，直至彻底干燥。
图2为5-FAM标记的多肽掺杂的ZIF-8(5-FP/ZIF-8)固体的扫描图，图3为5-FAM标记的多肽掺杂的ZIF-8固体的透射图，我们可以发现5-FP/ZIF-8为200纳米左右的固体颗粒，与ZIF-8固体相似，没有明显的形态变化，说明ZIF-8中的肽包覆并不影响ZIF-8的基本结构。图4为5-FAM标记的多肽掺杂的ZIF-8固体制备过程中上清液与形成的固体颗粒的荧光激发和发射谱图。我们发现离心后的5-FP/ZIF-8上清液只有微弱的荧光，下部沉淀的固体颗粒与5-FAM荧光标签的荧光发射峰相同，说明5-FAM标记的多肽成功掺杂进ZIF-8固体中。图5为不同浓度阿霉素溶液浸泡下的荧光发射谱图。将ZIF-8的固体颗粒分散在水溶液中，并浸入不同浓度的阿霉素中进行进一步的发光研究。ZIF-8的发光强度强烈地依赖于阿霉素浓度。发光强度随阿霉素浓度的增加而成比例下降，说明5-FAM标记的多肽掺杂的ZIF-8固体可用来负载及传感药物的负载情况。
实施例2
制备荧光标签修饰的多肽掺杂的ZIF-8：将冷冻的5-FAM多肽溶液室温下解冻，另外将溶于蒸馏水中，置于磁力搅拌器上进行搅拌。将Zn(NO3)2·6H2O配成0.25mol/L的水溶液。另外，将2-甲基咪唑配成2mol/L的水溶液。取5uM的5-FAM多肽100uL加入到500uLZn(NO3)2·6H2O溶液中搅拌10min，将5mL甲基咪唑溶液迅速加入到上述溶液中。室温搅拌0.5h。所有操作均在室温下进行。锌离子与甲基咪唑的摩尔比为1:80。混合各组分溶液后，混合物立即变得混浊。静置24-36h,6000-8000rpm离心10min。移除上层清液。得到的颗粒用水冲洗三次；；最后，将沉积物在40-60℃减压干燥12-15h。
称取2g 5-FAM多肽ZIF-8固体并加入2ml水。超声5-10min，然后加入不同浓度的阿霉素标准溶液(0～100μM)。室温孵育30s后，加入石英荧光试管。在494nm激发下，在500～700nm范围内测量荧光光谱。标签的荧光强烈依赖于药品载入的量，随药物载入量的增加荧光减弱。5分钟后离心。称取负载药物的ZIF-8固体分散于pH为6.3和6.8磷酸盐缓冲液(PBS)中。每隔30分钟使用荧光光谱在pH为6.3的PBS缓冲液中每隔30分钟用494nm激发，在500～700nm范围内测量荧光光谱。
图6和图7分别为负载了阿霉素的5-FP/ZIF-8固体在pH为6.3和6.8的PBS缓冲液中浸泡不同时间的荧光发射图，图8为pH为6.3透射图。随着固体颗粒逐渐破裂阿霉素的释放荧光逐渐增强，pH为6.3时0-12小时内荧光强度明显强于pH为6.8。说明5-FP/ZIF-8固体具有pH敏感性，在pH为6.3时可以有效释放药物，具有pH敏感性且可以有效传感药物的释放。
实施例3
制备荧光标签修饰的多肽掺杂的ZIF-8：将冷冻的5-FAM多肽溶液室温下解冻，另外将溶于蒸馏水中，置于磁力搅拌器上进行搅拌。将Zn(NO3)2·6H2O配成0.25mol/L的水溶液。另外，将2-甲基咪唑配成2mol/L的水溶液。取5uM的5-FAM多肽100uL加入到500uLZn(NO3)2·6H2O溶液中搅拌10min，将5mL甲基咪唑溶液迅速加入到上述溶液中。室温搅拌0.5h。所有操作均在室温下进行。锌离子与甲基咪唑的摩尔比为1:60。混合各组分溶液后，混合物立即变得混浊。静置24-36h,6000-8000rpm离心10min。移除上层清液。得到的颗粒用水冲洗三次；最后，将沉积物在40-60℃减压干燥12-15h。称取5-FAM标记的多肽掺杂的ZIF-8固体并加入2ml水。超声5-10min，然后加入不同浓度的阿霉素标准溶液(0～100μM)。5分钟后离心。移走上清液。
分别用掺杂5-FAM标记的多肽ZIF-8颗粒和只掺杂5-FAM标签的ZIF-8颗粒分别培养的Hep G2细胞。取对数生长期的Hep G2细胞，进行细胞计数，调整细胞浓度，分别称取0.1mg样品，溶解于1mL完全培养基中，超声15min，放置于30mm培养皿中紫外照射30min灭菌，得到浓度为0.1mg/mL的工作液，4℃保存备用。按照上述分组进行处理。5％CO 2，37℃恒温培养箱中分别培养2h；1mL/皿PBS清洗3次。按照1mL/皿加入PBS，上机拍摄。
图9为细胞实验的共聚焦显微镜的图像，图(b)为用掺杂5-FAM标记的多肽ZIF-8颗粒培养的细胞图像，图(c)为用只掺杂5-FAM标签的ZIF-8颗粒培养的细胞图像。我们发现，图(b)的荧光明显多于图(c),说明多肽的加入增加了细胞的通透性。
应当理解的是，对本领域普通技术人员来说，可以根据上述说明加以改进或变换，而所有这些改进和变换都应属于本发明所附权利要求的保护范围。
Claims (8)
1.一种荧光多肽掺杂金属有机框架纳米材料的制备方法，其特征在于，包括以下步骤：
（1）制备荧光标签修饰的多肽掺杂的ZIF-8：将冷冻的5-FAM修饰的组氨酸多肽溶液室温下解冻并溶于蒸馏水中得到溶液一，将Zn(NO3)2溶于蒸馏水中，置于磁力搅拌器上进行搅拌得到溶液二；将溶液一缓慢加入溶液二中得到混合溶液；室温搅拌0.5-1h，将2-甲基咪唑溶液迅速加入到所述混合溶液中；所有操作均在室温下进行；锌离子与2-甲基咪唑的摩尔比为1:30-1:80；所述组氨酸多肽能够增强细胞的通透性；
（2）静置后离心；移除上层清液，得到的颗粒用水冲洗将沉积物在40-60℃减压干燥，得到荧光多肽掺杂金属有机框架纳米材料5-FP/ZIF-8；
（3）在5-FP/ZIF-8中装载药物阿霉素。
2.根据权利要求1所述的制备方法，其特征在于，步骤（1）中：5-FAM肽与锌离子的摩尔比为1：250-500。
3.根据权利要求1所述的制备方法，其特征在于，步骤（1）所述加入500uL 0.25 mol/L的Zn(NO3)2·6H2O溶液，5mL 2mol/L的2-甲基咪唑溶液。
4.根据权利要求1所述的制备方法，其特征在于，步骤（2）所述的将沉淀溶液离心中，为中低速离心，离心机转速为6000-8000转/分，时间为20-30min。
5.根据权利要求1所述的制备方法，其特征在于，步骤（2）中沉淀洗涤三次，直至呈微碱性，为充分洗涤，每次超声5-10min。
6.根据权利要求1所述的制备方法，其特征在于，步骤（2）中减压干燥时温度不超过60℃，直至彻底干燥。
7.根据权利要求1-6任一所述的制备方法获得的荧光多肽掺杂金属有机框架纳米材料。
8.根据权利要求7所述的荧光多肽掺杂金属有机框架纳米材料在制备抗癌药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110221727.2A CN112972696B (zh) | 2021-02-27 | 2021-02-27 | 荧光多肽掺杂金属有机框架纳米材料及制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110221727.2A CN112972696B (zh) | 2021-02-27 | 2021-02-27 | 荧光多肽掺杂金属有机框架纳米材料及制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112972696A CN112972696A (zh) | 2021-06-18 |
| CN112972696B true CN112972696B (zh) | 2022-11-29 |
Family
ID=76351404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110221727.2A Active CN112972696B (zh) | 2021-02-27 | 2021-02-27 | 荧光多肽掺杂金属有机框架纳米材料及制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112972696B (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113621362B (zh) * | 2021-07-02 | 2023-07-07 | 济南大学 | Zif-8包裹发光型多酸复合材料的制备方法及硫离子检测应用 |
| CN114159583B (zh) * | 2021-12-08 | 2024-07-12 | 浙江大学杭州国际科创中心 | 一种zif-8多肽复合纳米制剂及其制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109164076A (zh) * | 2018-09-03 | 2019-01-08 | 中国药科大学 | 基于La-ZIF-8的荧光纳米探针、制备方法及其在生物荧光传感中的应用 |
| WO2020115754A1 (en) * | 2018-12-07 | 2020-06-11 | Rangasamy Naidu Educational Trust | Process for preparation of nanodiamond having fluorescent and sparkling properties |
-
2021
- 2021-02-27 CN CN202110221727.2A patent/CN112972696B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109164076A (zh) * | 2018-09-03 | 2019-01-08 | 中国药科大学 | 基于La-ZIF-8的荧光纳米探针、制备方法及其在生物荧光传感中的应用 |
| WO2020115754A1 (en) * | 2018-12-07 | 2020-06-11 | Rangasamy Naidu Educational Trust | Process for preparation of nanodiamond having fluorescent and sparkling properties |
Non-Patent Citations (3)
| Title |
|---|
| Jiaming Xuan et al..Peptide-Mediated Synthesis of Zeolitic Imidazolate Framework-8 with Controllable Morphology and Size.《Langmuir》.2020,第36卷(第46期), * |
| Pengcheng Zhang et al..Cellular Uptake and Cytotoxicity of Drug−Peptide Conjugates.《Bioconjugate Chemistry》.2013,第24卷(第4期), * |
| Yixuan Lin et al..Ligand-Modified Erythrocyte Membrane-Cloaked Metal−Organic Framework Nanoparticles for Targeted Antitumor Therapy.《Molecular Pharmaceutics》.2020,第17卷(第9期), * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112972696A (zh) | 2021-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110201163B (zh) | 一种透明质酸和聚多巴胺修饰的载药介孔二氧化钛纳米粒 | |
| CN112972696B (zh) | 荧光多肽掺杂金属有机框架纳米材料及制备方法和应用 | |
| CN103588933B (zh) | 多重仿生抗生物污染共聚物及其制备方法和应用 | |
| CN111558051B (zh) | 一种具有快速粘液渗透作用的复合纳米微球及其制备方法和应用 | |
| Zheng et al. | Novel fluorescent nitrogen-doped carbon dots derived from Panax notoginseng for bioimaging and high selectivity detection of Cr 6+ | |
| CN110063933B (zh) | 一种葡聚糖基纳米凝胶及其制备方法和应用 | |
| CN112773899A (zh) | 一种基于生物金属有机骨架材料的药物递送载体及其制备方法和应用 | |
| Wang et al. | Lipid coated upconverting nanoparticles as NIR remote controlled transducer for simultaneous photodynamic therapy and cell imaging | |
| CN111303868B (zh) | 近红外发光多肽自组装金纳米材料及其制备方法与应用 | |
| CN111892922B (zh) | 一种具有抗肿瘤效应的稀土上转换纳米颗粒/钒酸铋纳米复合材料的制备方法 | |
| CN111973573A (zh) | 一种磷酸钙纳米颗粒及其制备方法和应用 | |
| CN108310397B (zh) | 一种具有sers/荧光双模态靶向肿瘤细胞成像的诊疗试剂及其制备方法 | |
| Xu et al. | Histidine polypeptide-hybridized nanoscale metal–organic framework to sense drug loading/release | |
| CN100569802C (zh) | 亚细胞器靶向壳寡糖-脂肪酸嫁接物的合成方法 | |
| Dong et al. | pH-responsive Mannose-modified ferrocene Metal-Organic frameworks with rare earth for Tumor-targeted synchronous Chemo/Chemodynamic therapy | |
| CN113750252B (zh) | 一种钴掺杂的金属有机框架的纳米颗粒的制备方法及其应用 | |
| EP2825515B1 (en) | Coating metal oxide particles | |
| Zhang et al. | Dextran microgels loaded with ZnO QDs: pH‐triggered degradation under acidic conditions | |
| Wang et al. | Fabrication of hybridized nanoparticles with aggregation-induced emission characteristics and application for cell imaging | |
| CN112933247B (zh) | 一种溶剂诱导自组装金纳米颗粒材料的制备方法 | |
| Selim et al. | Albumin-conjugated cadmium sulfide nanoparticles and their interaction with KB cells | |
| CN106389386A (zh) | 一种用于药物包载与缓释的生物相容性交联微纳米材料及其构建工艺 | |
| CN113368045B (zh) | 一种磁性氧化响应的载药纳米胶束及其制备方法与应用 | |
| CN104998274B (zh) | 一种核‑壳结构纳米复合多功能载药体及其制备方法 | |
| CN110627937B (zh) | 仿细胞膜聚合物的制备方法、及其修饰壳聚糖-金自组装载药纳米粒子的制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |